A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.

A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.

BACKGROUND:Drug choice and metabolic changes with antiretroviral therapy contribute to cardiovascular risk in persons with HIV-1 infection. METHODS:A randomized, 12 week, open-label, comparative study of the impact on lipids of continuation of abacavir/lamivudine (ABC/3TC) plus efavirenz (EFV) or re...

Full description

Bibliographic Details
Main Authors:	Graeme J Moyle, Chloe Orkin, Martin Fisher, Jyoti Dhar, Jane Anderson, Edmund Wilkins, Jacqueline Ewan, Ramin Ebrahimi, Hui Wang, ROCKET 1 (Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial) Study Group
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4319732?pdf=render

Similar Items

A Comparison between the Efficiency of Vonavir (Tenofovir-Emtricitabine- Efavirenz) and Cobavir (Lamivudine-Zidovudine) with Efavirenz used for HIV Patients in Fasa, Iran
by: Saeideh Honarmand, et al.
Published: (2022-07-01)

Development and validation of analytical method for quantitation of Emtricitabine, Tenofovir, Efavirenz based on HPLC
by: Arun Ramaswamy, et al.
Published: (2018-02-01)

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
by: Cao Jing, et al.
Published: (2023-06-01)

Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
by: Wei-Chieh Huang, et al.
Published: (2021-10-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Effectiveness of tenofovir/emtricitabine versus zidovudine/lamivudine in combination with efavirenz in antiretro viral-naive HIV infected patients / Siti Mahanim Shaik Ismail
by: Shaik Ismail, Siti Mahanim
Published: (2015)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Safety and Efficacy of Fixed Drug Combination Tenofovir, Lamivudine and Efavirenz to Prevent Transmission of HIV
by: Pramendra Sirohi, et al.
Published: (2021-07-01)

Assessment of treatment outcomes for HIV Positives transitioned from Tenofovir/Lamivudine/Efavirenz to Tenofovir/Lamivudine/Dolutegravir in a Nigerian Tertiary Hospital
by: Omobola Yetunde Ojo, et al.
Published: (2023-12-01)

Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
by: Allison Martin, et al.
Published: (2011-01-01)

Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01)

Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis
by: Melanie R. Nicol, et al.
Published: (2019-09-01)

Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

PREDICTOR OF ANEMIA AMONG PEOPLE LIVING WITH HIV TAKING TENOFOVIR+LAMIVUDINE+EFAVIRENZ THERAPY IN JAYAPURA, PAPUA
by: Setyo Adiningsih, et al.
Published: (2023-01-01)

Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment
by: Yongquan Peng, et al.
Published: (2023-11-01)

HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
by: Juday T, et al.
Published: (2013-09-01)

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity <it>in vitro</it>: a mechanism of action study
by: Svarovskaia Evguenia S, et al.
Published: (2009-05-01)

Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV
by: Huan Xia, et al.
Published: (2021-12-01)

Brain antioxidants and hippocampal microanatomical alterations following the administration of Efavirenz/Lamivudine/Tenofovir disoproxil fumarate and Lamivudine/Nevirapine/Zidovudine in adult male Wistar rats
by: Innocent A. Edagha, et al.
Published: (2022-06-01)

Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV
by: Oliver T. Stirrup, et al.
Published: (2019-10-01)

Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China
by: Ya-Song Wu, et al.
Published: (2016-01-01)

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
by: Amit C Achhra, et al.
Published: (2014-01-01)

Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years
by: Dafeng Liu, et al.
Published: (2021-11-01)

Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats.
by: Frans Everson, et al.
Published: (2018-01-01)

Efavirenz in pregnancy
by: Polly Clayden, et al.
Published: (2010-11-01)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-07-01)

Efavirenz-induced urolithiasis.
by: Wirth, G, et al.
Published: (2006)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
by: Pobiner Bonnie F, et al.
Published: (2005-04-01)

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
by: Green, H, et al.
Published: (2007)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)<sub>2 </sub>vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
by: Focà Emanuele, et al.
Published: (2012-02-01)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
by: Dorward, J, et al.
Published: (2023)

Lamivudine‐conjugated and efavirenz‐loaded G2 dendrimers: Novel anti‐retroviral nano drug delivery systems
by: Esmaeel Mohammadi Pargoo, et al.
Published: (2021-09-01)

Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01)

Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults
by: Anchalee Avihingsanon, et al.
Published: (2017-08-01)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
by: Josep M Llibre, et al.
Published: (2015-01-01)

Increase in bone turnover markers in HIV patients treated with tenofovir disoproxil fumarate combined with raltegravir or efavirenz
by: Yonatan Oster, et al.
Published: (2020-12-01)